methyl N-(4,4-diphenyl-3-butenyl)-1,2,5,6-tetrahydro-3-pyridinecarboxylate | 95274-06-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: methyl N-(4,4-diphenyl-3-butenyl)-1,2,5,6-tetrahydro-3-pyridinecarboxylate
• 英文别名: methyl 1-(4,4-diphenylbut-3-en-1-yl)-1,2,5,6-tetrahydropyridine-3-carboxylate；methyl 1-(4,4-diphenylbut-3-enyl)-3,6-dihydro-2H-pyridine-5-carboxylate
• CAS: 95274-06-9
• 化学式: C₂₃H₂₅NO₂
• 分子量: 347.457
• InChiKey: PEBIDOLWCLZEAI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.8
• 重原子数：
  26
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.26
• 拓扑面积：
  29.5
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  methyl N-(4,4-diphenyl-3-butenyl)-1,2,5,6-tetrahydro-3-pyridinecarboxylate 在 alkali 作用下， 以 乙醇 、 水 为溶剂， 反应 3.0h， 以96%的产率得到1-(4,4-二苯基-3-丁烯基)-1,2,5,6-四氢-3-吡啶羧酸
  参考文献：
  名称：

  GAT1小型和大型结合剂的不同结合方式

  摘要：

  著名的γ-氨基丁酸（GABA）转运蛋白抑制剂GAT1共有一个小环状氨基酸的共同骨架，该小环状氨基酸通过烷基链连接到带有两个芳香环的部分上。Tiagabine是唯一经过FDA批准的GAT1抑制剂，就是一个典型的例子。一些小的氨基酸，如（R）-戊二酸，是GAT1的中等至强结合剂，而类似的化合物，例如脯氨酸，则是非常弱的结合剂。当被4,4-二苯基丁-3-烯-1-基（DPB）或4,4-双（3-甲基噻吩-2-烯基）但是3-烯-1-基（BTB）基团取代时，得到的化合物的p K i和pIC 50相似即使纯氨基酸具有非常不同的值，也可以使用这些值。为了研究小氨基酸及其取代的对等体是否具有相似的结合模式，我们合成了小氨基酸的丁基，DPB和BTB取代衍生物。受对接研究结果的支持，我们不仅针对未取代和取代的氨基酸，还针对强结合和弱结合氨基酸提出了不同的结合方式。这些数据得出的结论是，采用基于片段的方法，不应使用

  DOI：

  10.1002/cmdc.201500534
• 作为产物：
  描述：

  1,2,5,6-四氢吡啶-3-羧酸甲酯 、 (4-溴-1-苯基丁-1-烯基)苯 在 potassium carbonate 作用下， 以 丙酮 为溶剂， 反应 15.0h， 以69%的产率得到methyl N-(4,4-diphenyl-3-butenyl)-1,2,5,6-tetrahydro-3-pyridinecarboxylate
  参考文献：
  名称：

  Orally Active and Potent Inhibitors of γ-Aminobutyric Acid Uptake

  摘要：

  3-Pyrrolidineacetic acid (1a), certain piperidinecarboxylic acids--i.e., 3-piperidinecarboxylic acid (2a), 1,2,5,6-tetrahydro-3-pyridinecarboxylic acid (3a), and cis-4-hydroxy-3-piperidinecarboxylic acid (4a)--cis-3-aminocyclohexanecarboxylic acid (5a, cis-3-ACHC), and gamma-aminobutyric acid (6a, GABA) itself are among the most potent inhibitors of [3H]GABA uptake by neurons and glia in vitro. These hydrophilic amino acids, however, do not readily enter the central nervous system in pharmacologically significant amounts following peripheral administration. We now report that N-(4,4-diphenyl-3-butenyl)-3-piperidinecarboxylic acid (2b) is a specific GABA-uptake inhibitor that is more potent, more lipophilic and, in limited testing, as selective as 2a. Similar results were obtained with the N-(4,4-diphenyl-3-butenyl) derivatives of 1a, 3a, and 4a. By contrast, N-(4,4-diphenyl-3-butenyl) derivatives of 5a and 6a were not more potent than the parent amino acids and appear to inhibit GABA uptake, at least in part, by a nonselective mechanism of action. The N-(4,4-diphenyl-3-butenyl)amino acids 1b-4b exhibit anticonvulsant activity in rodents following oral or intraperitoneal administration [Yunger, L.M.; et al. J. Pharmacol. Exp. Ther. 1984, 228, 109].

  DOI：

  10.1021/jm50001a020

文献信息

• N-substituted azaheterocyclic carboxylic acids and their esters
  申请人：SMITHKLINE BECKMAN CORPORATION

  公开号：EP0066456B1

  公开（公告）日：1985-04-24
• US4383999A
  申请人：——

  公开号：US4383999A

  公开（公告）日：1983-05-17
• Orally Active and Potent Inhibitors of γ-Aminobutyric Acid Uptake
  作者：Fadia E. Ali、William E. Bondinell、Penelope A. Dandridge、James S. Frazee、Eleanor Garvey、Gerald R. Girard、Carl Kaiser、Thomas W. Ku、John J. Lafferty、George I. Moonsammy、Hye-Ja Oh、Julia A. Rush、Paulette E. Setler、Orum D. Stringer、Joseph W. Venslavsky、Beth W. Volpe、Libby M. Yunger、Charles L. Zirkle

  DOI：10.1021/jm50001a020

  日期：1985.5

  3-Pyrrolidineacetic acid (1a), certain piperidinecarboxylic acids--i.e., 3-piperidinecarboxylic acid (2a), 1,2,5,6-tetrahydro-3-pyridinecarboxylic acid (3a), and cis-4-hydroxy-3-piperidinecarboxylic acid (4a)--cis-3-aminocyclohexanecarboxylic acid (5a, cis-3-ACHC), and gamma-aminobutyric acid (6a, GABA) itself are among the most potent inhibitors of [3H]GABA uptake by neurons and glia in vitro. These hydrophilic amino acids, however, do not readily enter the central nervous system in pharmacologically significant amounts following peripheral administration. We now report that N-(4,4-diphenyl-3-butenyl)-3-piperidinecarboxylic acid (2b) is a specific GABA-uptake inhibitor that is more potent, more lipophilic and, in limited testing, as selective as 2a. Similar results were obtained with the N-(4,4-diphenyl-3-butenyl) derivatives of 1a, 3a, and 4a. By contrast, N-(4,4-diphenyl-3-butenyl) derivatives of 5a and 6a were not more potent than the parent amino acids and appear to inhibit GABA uptake, at least in part, by a nonselective mechanism of action. The N-(4,4-diphenyl-3-butenyl)amino acids 1b-4b exhibit anticonvulsant activity in rodents following oral or intraperitoneal administration [Yunger, L.M.; et al. J. Pharmacol. Exp. Ther. 1984, 228, 109].
• Different Binding Modes of Small and Large Binders of GAT1
  作者：Thomas Wein、Marilena Petrera、Lars Allmendinger、Georg Höfner、Jörg Pabel、Klaus T. Wanner

  DOI：10.1002/cmdc.201500534

  日期：2016.3.4

  of GAT1, but similar compounds, such as proline, are very weak binders. When substituted with 4,4‐diphenylbut‐3‐en‐1‐yl (DPB) or 4,4‐bis(3‐methylthiophen‐2‐yl)but‐3‐en‐1‐yl (BTB) groups, the resulting compounds have similar pKi and pIC50 values, even though the pure amino acids have very different values. To investigate if small amino acids and their substituted counterparts share a similar binding mode

  著名的γ-氨基丁酸（GABA）转运蛋白抑制剂GAT1共有一个小环状氨基酸的共同骨架，该小环状氨基酸通过烷基链连接到带有两个芳香环的部分上。Tiagabine是唯一经过FDA批准的GAT1抑制剂，就是一个典型的例子。一些小的氨基酸，如（R）-戊二酸，是GAT1的中等至强结合剂，而类似的化合物，例如脯氨酸，则是非常弱的结合剂。当被4,4-二苯基丁-3-烯-1-基（DPB）或4,4-双（3-甲基噻吩-2-烯基）但是3-烯-1-基（BTB）基团取代时，得到的化合物的p K i和pIC 50相似即使纯氨基酸具有非常不同的值，也可以使用这些值。为了研究小氨基酸及其取代的对等体是否具有相似的结合模式，我们合成了小氨基酸的丁基，DPB和BTB取代衍生物。受对接研究结果的支持，我们不仅针对未取代和取代的氨基酸，还针对强结合和弱结合氨基酸提出了不同的结合方式。这些数据得出的结论是，采用基于片段的方法，不应使用